Compositions for use in the treatment of diabetes

Abstract

This invention relates to compositions for use in the treatment of diabetes, for example type-2 diabetes; obesity; and/or metabolic syndrome. Specifically, the invention relates to a composition for use in the treatment of diabetes, the composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations each thereof. Also disclosed is use in the treatment of obesity and use in the treatment of metabolic syndrome.

1 . A method of treating diabetes, the method comprising administering a pharmaceutical composition comprising at least one of diindolylmethane; indole-3-carbinol; embelin; [6]-gingerol; and [6]-shogaol, or combinations of each thereof to a subject in need thereof. 
     
     
         2 . The method of  claim 1 , wherein the composition comprises embelin. 
     
     
         3 . The method of  claim 1 , wherein the composition comprises a pharmaceutically acceptable amount of embelin. 
     
     
         4 . The method of  claim 1 , wherein the composition comprises from 10 −12  to 10 −4  mol/L of embelin. 
     
     
         5 . The method of  claim 1 , wherein the composition comprises 10 −4  mol/L of embelin. 
     
     
         6 . The method of  claim 1 , wherein the composition further comprises glucose. 
     
     
         7 . The method of  claim 6 , wherein the composition comprises 5.6 mM glucose. 
     
     
         8 . The method of  claim 6 , wherein the composition comprises 16.7 mM glucose. 
     
     
         9 . The method of  claim 2 , further comprising administering glucose before the composition comprising embelin. 
     
     
         10 . The method of  claim 2 , further comprising co-administering glucose with the composition comprising embelin. 
     
     
         11 . The method of  claim 2 , further comprising administering glucose after the composition comprising embelin. 
     
     
         12 . The method of  claim 2 , wherein the composition is administered in an amount such that the embelin is administered in an amount of 0.1 μmol/kg to 50 μmol/kg body weight of said subject. 
     
     
         13 . The method of  claim 2 , wherein the composition is administered in combination with glucose in an amount such that the glucose is administered in an amount of 18 mmol/kg body weight of said subject. 
     
     
         14 . A method of treating obesity, the method comprising administering a pharmaceutical composition comprising embelin to a subject in need thereof. 
     
     
         15 . A method of treating metabolic syndrome, the method comprising administering a pharmaceutical composition comprising embelin to a subject in need thereof. 
     
     
         16 - 18 . (canceled)